A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared
to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to
moderate, symptomatic COVID-19. It is anticipated that approximately 80 patients will be
randomized into the study in a 1:1 ratio to 100 mg APX-115 or placebo arm.